t
MedPal AI plc announced its total voting rights as at 27 February 2026. The company reported 449,099,640 ordinary shares of 1 pence each in issue, with none held in treasury. This resulted in a total of 449,099,640 voting rights.
| Date | 27 Feb 2026 |
| Time | 09:00:00 |
| Category | Capital structure |
| ID | 0417U |
27 February 2026
MedPal AI plc
("MedPal AI" or the "Company")
Total Voting Rights
In accordance with the Financial Conduct Authority's Disclosure and Transparency Rules, the Company hereby announces that as at 27 February 2026 there were 449,099,640 ordinary shares of 1 pence each in issue, none of which are held in treasury. Therefore, the total number of voting rights in the Company is 449,099,640.
The above figure of 449,099,640 may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.
The Directors of the Company are responsible for the release of this announcement.
For further information visit www.medpalai.com or contact the following:
Enquiries:
|
MedPal AI plc Jason Drummond, Chief Executive Officer
|
Via Square1 Consulting |
|
Cairn Financial Advisers LLP Louise O'Driscoll/Jo Turner
|
+44 (0) 20 7213 0880 |
|
Clear Capital Markets Limited Bob Roberts
|
+44 (0) 20 3869 6080 |
|
Square1 Consulting David Bick |
+44 (0) 20 7929 5599 +44 (0) 7831 381201 |
About MedPal AI
MedPal AI is a UK-based digital health company specialising in AI-driven wellness management. Its core app aggregates data from over 100 wearables and health apps (e.g. Apple Health, Fitbit, Garmin) into a unified profile, offering non-clinical, personalised lifestyle guidance through its AI wellness coach. The Company is also developing conversational AI to provide voice-based, real-time health insights, alerts, and recommendations.
Through its wholly owned subsidiary MedPal Limited, the Company operates a 24/7 AI-powered automated pharmacy distribution centre, providing nationwide NHS and private prescription services. The facility leverages advanced robotic dispensing technology integrated with AI triage to deliver rapid, cost-effective medication fulfilment with same-day and next-day delivery capabilities.
MedPal AI has a partnership agreement with Epassi UK Limited, which will, for a limited time, grant exclusive, zero-cost access to the MedPal AI app across Epassi's network of 11M+ employees at major firms like Siemens and Volvo. Beyond consumers, MedPal AI plans to expand via B2B licensing to healthcare providers, businesses, and insurers, with potential use in insurance-linked wellness programs to reduce premiums and drive new revenue through institutional partnerships. The Company also has a partnership agreement with Independent Gyms Ltd.
Forward Looking Statements
This announcement contains forward-looking statements relating to expected or anticipated future events and anticipated results that are forward-looking in nature and, as a result, are subject to certain risks and uncertainties, such as general economic, market and business conditions, competition for qualified staff, the regulatory process and actions, technical issues, new legislation, uncertainties resulting from potential delays or changes in plans, uncertainties resulting from working in a new political jurisdiction, uncertainties regarding the results of exploration, uncertainties regarding the timing and granting of prospecting rights, uncertainties regarding the timing and granting of regulatory and other third party consents and approvals, uncertainties regarding the Company's or any third party's ability to execute and implement future plans, and the occurrence of unexpected events.